Viral disease

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Retrieved on: 
Tuesday, April 2, 2024
COVID19, COVID, Trawsfynydd, Pfizer, Drug, Novartis, General partnership, Patient, CYP, Oseltamivir, CDK, Aes, Ritonavir, SARS-CoV-2, Delta, Infection, Viral disease, Omicron, Therapy, OrbiMed, Safety, Pharmacokinetics, Toxicology, Lilly, Bone marrow suppression, CSO, GLP, Mergers and acquisitions, Pharmaceutical industry

Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)

Key Points: 
  • Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
    Companies to host joint webcast, April 2, 2024 at 8:30 a.m.
  • Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd’s outstanding equity interests.
  • These proceeds will be used to advance the Traws’ programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.
  • Topline data are expected H2 2024
    Phase 2 study planned to be initiated in H2 2024.

Morris & Dickson is the First U.S. Distributor for Bavarian Nordic’s JYNNEOS®, the Only FDA-approved Mpox Vaccine

Retrieved on: 
Wednesday, April 3, 2024
Infectious Diseases, Pharmaceutical, Health, Disease, Smallpox, Virus, Mpox, Viral disease, Infection, CDC, Bavarian Nordic, Family, FDA, Pharmaceutical industry

Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic’s newly launched mpox vaccine, JYNNEOS®.

Key Points: 
  • Morris & Dickson is proud to announce it is the first U.S. distributor of Bavarian Nordic’s newly launched mpox vaccine, JYNNEOS®.
  • As the only FDA-approved mpox vaccine, JYNNEOS is now commercially available in the U.S., marking a significant expansion for access.
  • Bavarian Nordic announced its commercial entry into the US on April 2, noting the ongoing need for the vaccine.
  • “We are proud to be a key partner in expanding access to this first-to-market vaccine,” says Layne Martin, head of Specialty at Morris & Dickson.

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, Research, Pharmacology, LD, Survival, Serum, ALS, Science, PD, Houston Methodist Hospital, Patient, Regulatory affairs, Granulocyte-macrophage colony-stimulating factor, FD, GM-CSF, Nebraska Medicine, COYA, University, IPO, Senior, Society, IND, Commerce, Viral disease, Therapy, Frontotemporal dementia, FDA, FTD, Pharmaceutical industry

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2023.
  • COYA 302 is Coya’s combination of its proprietary LD IL-2 formulation with the immunomodulatory drug CTLA4-Ig.
  • “We believe that we have under-promised and over-delivered in executing on numerous deliverables in 2023 that have brought value to Coya,” commented Howard Berman, Ph.D., Chief Executive Officer of Coya.
  • Net loss was $8.0 million for the year ended December 31, 2023, compared to net loss of $12.2 million for the year ended December 31, 2022.

Telehealth Utilization Decreased Nationally and in Every US Census Region in December

Retrieved on: 
Thursday, March 14, 2024
Diagnosis, Diabetes, Hypertension, Telehealth, COVID-19, Viral disease, Infection, Medicaid, Telephone numbers in Hungary, Medicare, Medicare Advantage

NEW YORK, March 14, 2024 /PRNewswire/ -- Telehealth utilization decreased nationally and in every US census region in December 2023, according to FAIR Health's Monthly Telehealth Regional Tracker. The decreases followed a month of increases nationally and in every region in November. In December, national utilization declined 3.9 percent, falling from 5.1 percent of medical claim lines in November to 4.9 percent in December.1 The largest regional decrease occurred in the West, where the percentage of medical claim lines fell 9.7 percent. In the Northeast the decrease was 3.3 percent; in the Midwest it was 2.9 percent and, in the South, 2.5 percent. The data represent the privately insured population, including Medicare Advantage and excluding Medicare Fee-for-Service and Medicaid.

Key Points: 
  • The decreases followed a month of increases nationally and in every region in November.
  • In December, for the first time since September, COVID-19 joined the rankings of the top five telehealth diagnoses nationally, entering in third place.
  • In December, mental health conditions remained the number one telehealth diagnosis nationally and in every region, though it continued to decline in its percentage of telehealth claim lines everywhere.
  • In December 2023, utilization of audio-only telehealth services increased nationally and in every region, in both rural and urban areas.

Kao and Earth Collaborate in the Field of “Insect (Mosquito) Control” in Thailand

Retrieved on: 
Thursday, February 29, 2024
Infectious Diseases, Other Health, Other Retail, Health, Retail, Ministry, Multimedia, ARS, Viral disease, Public health, Urbanization, Life, Learning, Climate, School, Dengue fever, Death, Fever Dream, Corporation, Kao Corporation, Research, Vaccine

It will be launched in Thailand from July 2024, where Earth has been active domestically for about 40 years.

Key Points: 
  • It will be launched in Thailand from July 2024, where Earth has been active domestically for about 40 years.
  • Earth Corporation founded ARS Chemical (Thailand) Co., Ltd. (now Earth (Thailand) Co., Ltd.) in Thailand in 1980.
  • Earth (Thailand) single-handedly manages development, sales and distribution of, for example, the insect control item brand ARS as a local subsidiary in Thailand.
  • Both Kao and Earth believe that this product will help people living in areas suffering from dengue fever.

Minister MacAulay announces support for Animal Health Canada's work to prevent and prepare for animal disease outbreaks

Retrieved on: 
Thursday, March 7, 2024
FAP, CFIA, Livestock, Food safety, Deer, Investment, Viral disease, Pig, Executive Schedule, Cattle, Animal, Sheep, AAFC, ASF, Government, Goat, FMD, Risk, African swine fever virus, Food, Canadian Food Inspection Agency, Health, Pithing, Disease, Foot, Research, Human

Today the Honourable Lawrence MacAulay, Minister of Agriculture and Agri-Food, announced an investment of up to $1,697,850 to Animal Health Canada to support their role in foreign animal disease prevention and preparedness efforts in Canada, including for African swine fever (ASF) and Foot and Mouth Disease (FMD).

Key Points: 
  • Today the Honourable Lawrence MacAulay, Minister of Agriculture and Agri-Food, announced an investment of up to $1,697,850 to Animal Health Canada to support their role in foreign animal disease prevention and preparedness efforts in Canada, including for African swine fever (ASF) and Foot and Mouth Disease (FMD).
  • Animal Health Canada brings together the agriculture industry, and federal, provincial and territorial partners to provide input on a cohesive, functional and responsive farmed animal health and welfare system in Canada.
  • Animal Health Canada's coordination role with partners and stakeholders has been key to Canada's animal disease prevention, and to ensuring our livestock sector is ready in the event of an outbreak.
  • -       The Honourable Lawrence MacAulay, Minister of Agriculture and Agri-Food
    "We're pleased we are continuing our collaboration with industry and government to not only prevent and control African swine fever in Canada, but other foreign animal disease outbreaks."

Coya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral Sclerosis

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, FTD, Macrophage, Patient, Therapy, Viral disease, Frontotemporal dementia, Vision, COYA, PD, IND, Disease, Coya, File, ALS

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces that it is expanding its pipeline in neurodegenerative conditions for COYA 302 beyond ALS to include frontotemporal dementia (FTD) and Parkinson’s disease (PD).

Key Points: 
  • Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces that it is expanding its pipeline in neurodegenerative conditions for COYA 302 beyond ALS to include frontotemporal dementia (FTD) and Parkinson’s disease (PD).
  • FTD and PD share a similar disease pathogenesis to ALS that is associated with a heightened proinflammatory cascade involving dysfunctional Tregs and proinflammatory microglia and macrophages.
  • COYA 302 has the potential to be disease modifying by targeting multiple dysregulated immune pathways while restoring function in anti-inflammatory Treg function.
  • With COYA 302, we have taken a page from the playbook of oncology and viral disease where combination therapies have been transformational.

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis

Retrieved on: 
Tuesday, January 9, 2024
Myocarditis, Patient, European, Therapy, Research, Viral disease, Survival, Facial muscles, Fatigue, ARCHER, Heart failure, Freedom, Lightheadedness, Prognosis, Rest, Arrhythmia, Risk, Cancer, TSX, Arthralgia, Disease, Safety, Fever, Genetically modified bacteria, FDA, Inflammation, Biomarker, Marketing, Messenger, Clinical trial, Headache, Chest pain, CRDL, Pharmaceutical industry

Results from the ARCHER trial will assist in further understanding the therapeutic potential of CardiolRx™ and will complement the important clinical data from our ongoing MAvERIC-Pilot Phase II study in patients presenting with recurrent pericarditis."

Key Points: 
  • Results from the ARCHER trial will assist in further understanding the therapeutic potential of CardiolRx™ and will complement the important clinical data from our ongoing MAvERIC-Pilot Phase II study in patients presenting with recurrent pericarditis."
  • The ARCHER trial has been designed in collaboration with an independent steering committee comprising distinguished thought leaders in heart failure and myocarditis from international centers of excellence.
  • The trial is expected to enroll 100 patients at pre-eminent cardiovascular research centers in North America, France, Brazil, and Israel.
  • Orphan drug designation programs were established to provide life sciences companies with incentives to develop new therapies for rare diseases.

Doctors and Experts around the World Call for Urgent Action to Prevent Liver Health Crisis

Retrieved on: 
Tuesday, December 12, 2023
Tax, Policy, Prevalence, Hope, JD, Hepatology, Health, Viral disease, Hanoi Medical University, Patient, Liver disease, GLI, Salix Pharmaceuticals

“Our continued exploration of the scope and scale of the impact of liver diseases gives us both pause and hope.

Key Points: 
  • “Our continued exploration of the scope and scale of the impact of liver diseases gives us both pause and hope.
  • National experts have identified the greatest threats to liver health in their communities.
  • Now, those who care about liver health and its related conditions must urge their national leaders to prioritize and implement solutions.
  • The Liver Health is Public Health initiative is made possible thanks to the support of Sanofi and Salix Pharmaceuticals.

Vaccine Partner Valneva receives FDA approval for the World's first chikungunya vaccine using Albumedix' Recombumin®

Retrieved on: 
Wednesday, November 22, 2023
Chikungunya, Vaccine, LTD, Research, Safety, Viral disease, Mosquito-borne disease, Sartorius, Temperature, FDA, Pharmaceutical industry

NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus. Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.

Key Points: 
  • Valneva's lyophilized chikungunya vaccine IXCHIQ® is the first in the world to be FDA approved against the viral disease, addressing an unmet medical need.
  • Recombumin®, a chemically defined, human and animal origin-free recombinant human albumin, is a critical enabler for the manufacture and formulation of Valneva's chikungunya vaccine.
  • NOTTINGHAM, England, Nov. 22, 2023 /PRNewswire/ -- The FDA on 10th November 2023 announced the approval of IXCHIQ®, Valneva's vaccine against the chikungunya virus.
  • Notably, this is the first vaccine against the mosquito-borne disease to have been granted marketing approval by the FDA.